MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40256-017-0240-5

Медицинская библиотека · American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018

The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review.

Elshafay Abdelrahman, Truong Duy Hieu, AboElnas Mohamed M, Idrees Hossam, Metwali Hatem G, Vuong Nguyen Lam, Saad Omar Ahmed, Hirayama Kenji, Huy Nguyen Tien

СтатьяСистематический обзорПеревод в очереди

Аннотация

INTRODUCTION

The efficacy of endothelin receptor antagonists (ERAs) in the management of Eisenmenger syndrome (ES) remains controversial. The aim of this study is to systemically review the safety and effects of ERAs in improving the quality of life and basic cardiac functions of these patients.

METHODS

Twelve databases were searched, including PubMed, Web of Science, Scopus, Virtual Health Library, World Health Organization (WHO) Global Health Library, Google Scholar, POPLINE, Systems for Information of Grey Literature in Europe, New York Academy of Medicine, ClinicalTrials.gov, metaRegister of Controlled Trials and the WHO International Clinical Trials Registry Platform, through August 2016. We included randomized clinical trials addressing the effect of ERAs on cardiac functions in patients with ES. The quality of studies was assessed using the Cochrane Collaboration tool.

RESULTS

We included two trials represented by four papers, of which three papers reported the efficacy of bosentan against placebo and one paper reported the results of a combination of bosentan and sildenafil versus placebo and bosentan. One trial showed a significant effect of bosentan treatment over placebo on indexed pulmonary vascular resistance and mean pulmonary artery pressure, but a non-significant increase in 6-min walk distance and a non-significant effect on systemic pulse oximetry. The other trial reported the safe but non-significant effect of combination therapy of bosentan and sildenafil compared with bosentan and placebo.

CONCLUSIONS

This study demonstrated safety and improved hemodynamic effects of bosentan in ES, with a controversial effect on exercise capacity. Further randomized controlled trials with longer follow-up duration are needed to confirm these results.

Для цитирования: Elshafay Abdelrahman, Truong Duy Hieu, AboElnas Mohamed M, Idrees Hossam, Metwali Hatem G, Vuong Nguyen Lam, Saad Omar Ahmed, Hirayama Kenji, Huy Nguyen Tien. The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review.. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2018. DOI: 10.1007/s40256-017-0240-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.